Soliton Files Special 510(k) with FDA for its Generation II RAP Device
Key step towards limited launch mid-2020 Houston, TX – February 11, 2020 –Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has filed for Special […]
Soliton Announces Successful Completion of Safety Testing at SGS to Support FDA Filing for Second Generation Device
Houston, TX – December 18, 2019 – Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced its Rapid Acoustic Pulse (“RAP”) device successfully completed the IEC 60601 safety […]
Soliton To Announce Keloid and Hypertrophic Scar Clinical Trial Data on October 24, 2019
Results to be Presented at American Society for Dermatologic Surgery Annual Meeting Houston, TX – October 8, 2019 – Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today […]
Soliton Announces Site Selected for Clinical Trial to Treat Fibrotic Scars
Successful trials demonstrating Rapid Acoustic Pulse (RAP) technology to reduce keloid and hypertrophic scars may be indicative of a wider range of fibrosis-related indication Houston, TX – September 10, 2019 – Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University […]
Soliton Announces Positive Results Demonstrated from Longer RAP Treatment
Dosing Effect Identified with Acoustic Subcision Treatment of Cellulite Houston, TX – August 20, 2019 – Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced results […]
Soliton Treats First Patients in Pivotal Cellulite Trial
Houston, TX – August 14, 2019 –- Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has treated the first patients in its pivotal […]
Soliton Announces Patient Recruitment Has Begun for Pivotal Cellulite Trial
Houston, TX – August 12, 2019 – Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has initiated patient recruitment for its upcoming pivotal […]
Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite
RAP technology combines selective disruption of fibrotic structures with production of new collagen in single non-invasive procedure Houston, TX – June 4, 2019 – Soliton, Inc., (NASDAQ:SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson […]
Soliton to Initiate Pivotal Cellulite Trial after Positive Proof-of-Concept Trial Results with 20-47% Improvement in Cellulite Severity Score
Proof of Concept Trial Reveal Significant Reduction in Cellulite with No Bruising, No Swelling and No Downtime after single 20-Minute non-invasive Procedure; Justifies proceeding with Pivotal Trial. Houston, TX – May 29, 2019 – Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed […]
Soliton Receives FDA 510(k) Clearance of its Acoustic Shockwave RAP Device
Houston, TX – May 28, 2019 – Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has received clearance from the U.S. Food & Drug […]
